Chronic hepatitis B in rheumatic diseases: issues of screening and reactivation of infection: A review [PDF]
Терапевтический архивPatients with rheumatic diseases infected with hepatitis B virus (HBV) are difficult to manage not only due to the presence of risk factors for the development and rapid progression of liver cirrhosis, but also due to the likelihood of reactivation of ...
Galina I. Gridneva +2 more
doaj +1 more source
Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study [PDF]
, 2023 Viking Huss +16 more
openalex +1 more source
Impact of biological agents and tissue engineering approaches on the treatment of rheumatic diseases [PDF]
, 2010 The treatment of rheumatic diseases has been the focus of many clinical studies aiming to achieve the best combination of drugs for symptom reduction.
Martins, Albino +4 more
core +1 more source
Advanced Science, EarlyView.Carrier‐free myricetin‐arginine conjugate nanozymes (MANZs) have been fabricated through a Mannich reaction and spontaneous self‐assembly. MANZs selectively accumulate in inflamed joints by targeting M1 macrophages via CAT2‐mediated uptake. The nanozymes can effectively modulate macrophage polarization, suppress osteoclast differentiation, and mitigate
Jiachang Hong +14 more
wiley +1 more source
Hypomethylation of CYP2E1 and DUSP22 Promoters Associated With Disease Activity and Erosive Disease Among Rheumatoid Arthritis Patients. [PDF]
, 2018 OBJECTIVE:Epigenetic modifications have previously been associated with rheumatoid arthritis (RA). In this study, we aimed to determine whether differential DNA methylation in peripheral blood cell subpopulations is associated with any of 4 clinical ...
Barcellos, Lisa F +13 more
core +1 more source
Advanced NanoBiomed Research, EarlyView.This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari +5 more
wiley +1 more source
Frontiers in MedicineObjectivesTo assess efficacy of withdrawal or tapering biologic disease-modifying antirheumatic drugs (bDMARDs) vs. maintaining a standard regimen in patients with axial spondyloarthritis (axSpA) to sustain remission.MethodsWe conducted a systematic ...
Hye Sang Park +9 more
doaj +1 more source
High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): A multicenter randomized clinical trial [PDF]
, 2016 Objectives: To determine whether prolonged intensive disease-modifying antirheumatic drug (DMARD) treatment (PRINT) leads to high remission and low relapse rates in patients with severe rheumatoid arthritis (RA).
Chen, Li-Na +24 more
core +3 more sources
Mucosal‐Associated Invariant T Cells in Rheumatic Diseases
Arthritis &Rheumatology, EarlyView.Mucosal‐associated invariant T (MAIT) cells are innate‐like T cells defined by their semi‐invariant T cell receptor and restriction by the major histocompatibility complex class I–related molecule (MR1). These cells are primarily activated by microbial‐derived metabolites presented by MR1 or by cytokines.
Manon Lesturgie‐Talarek +7 more
wiley +1 more source
Is vaccination against viral hepatitis B safe and immunogenic in patients with rheumatic diseases?
Современная ревматологияImpressive successes have been achieved in the fight against viral hepatitis B (HBV), but victory over this infection has not yet been achieved. According to various estimates, there are 6–12.5 times more patients with resolved HBV who are carriers of ...
G. I. Gridneva +2 more
doaj +1 more source